Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 4Prostatic Neoplasms 3Carcinoma, Hepatocellular 3Pain, Postoperative 2Lung Neoplasms 2Inflammation 2Stomach Neoplasms 1Postoperative Nausea and Vomiting 1Pancreatic Neoplasms 1Neuroma, Acoustic 1Neoplasms 1Melanoma 1Liver Neoplasms 1Liver Diseases 1Gynecological Laparoscopic Surgery 1Esophageal Neoplasms 1Emergence Delirium 1Chronic Pain 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Sufentanil × Clear all
NCT00943566 2015-09-15

A Safety and Efficacy Study of Sufentanil Transdermal System in Patients With Chronic Pain Due to Cancer

Labtec GmbH

Phase 2 Withdrawn

Neoplasms, Pain, Chronic Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡